CECarson C. Edwards

Carson C. Edwards

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carson C. Edwards has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Phase II Study in Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer Evaluating Carboplatin/Taxol/Pembrolizumab in patients receiving Neoadjuvant Chemotherapy (NACT) followed by Pembrolizumab Maintenance with or without Olaparib

    by Carson C. Edwards, Kati A. Turner, Kaitlyn Kincaid, Peter W. Ketch, Anna Wilbanks, Kathryn Schlenker, Warner Huh, Charles Leath, Michael D. Toboni, Rebecca C. Arend, et al.

    BackgroundPembrolizumab, a PD-1 immune checkpoint inhibitor, has shown promise in various cancers, but its role in ovarian cancer remains under investigation. While the current standard of care (SOC) is initially effective for epithelial ovarian cancer (EOC), approximately 70% of patients relapse within 3 years of completing upfront treatment, highlighting an unmet need for therapies that extend time to first progression. The survival benefit observed with hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking surgery (IDS), combined with the potential for checkpoint inhibitors to augment antitumor immunity alongside cytotoxic and hyperthermic stimuli, provides the rationale for this novel trial combining neoadjuvant chemotherapy (NACT), immunotherapy, and HIPEC in the upfront treatment of advanced EOCPatients and MethodsThis double-arm, open-label phase II trial plans to enroll 40 patients. Patients with histologically confirmed diagnosis of FIGO stage III or IV EOC who is a candidate for neoadjuvant chemotherapy with planned IDS are eligible. Patients will receive pembrolizumab 200 mg in combination with carboplatin and paclitaxel for 3 21-day treatment cycles prior to IDS and 3 treatment cycles following IDS. During IDS, the first 10 patients who are eligible for HIPEC will receive 100 mg/m2 of cisplatin heated to 40-42°C intraperitoneally over 90 minutes. All patients will continue 2 years of maintenance pembrolizumab, and BRCA1/2-mutated or homologous recombination deficient patients will also receive maintenance olaparib in combination with pembrolizumab.ConclusionThe findings of this study have the potential to change clinical practice by informing potential primary and maintenance treatment options for further clinical trial assessment in advanced ovarian cancer.

  • Open Access

    Oxidative DNA Damage Is Associated with Immune Remodeling and Therapeutic Response in High-Grade Serous Ovarian Cancer

    by Carson C. Edwards, Jenna M. Hedlich-Dwyer, Jianqing Zhang, Valeria L. Dal Zotto, Dongquan Chen, Rebecca C. Arend, Natalie R. Gassman

    Background/Objectives: High-grade serous ovarian cancer (HGSOC) shows variable response to platinum-based neoadjuvant chemotherapy (NACT), with outcomes strongly linked to upfront treatment sensitivity. We evaluated whether oxidative DNA damage in pathologic samples is associated with improved clinical outcomes and reflects tumor–immune interactions. Methods: We analyzed matched pre- and post-NACT tumors from patients with stage III–IV HGSOC using Repair Assisted Damage Detection (RADD) to quantify total and oxidative DNA lesions (oxRADD). Gene expression profiling was performed on a subset of tumors using the NanoString PanCancer I/O 360. Associations with homologous recombination status, platinum sensitivity, recurrence, and survival were assessed. Results: Higher pre-NACT oxidative DNA damage was observed in tumors from patients who later recurred. Among recurrent tumors, elevated oxidative lesions were associated with improved overall survival (61.8 vs. 35.0 months; HR = 0.42, p = 0.037). Oxidative damage predicted recurrence (AUC = 0.71), supporting its utility in risk stratification. Tumors with serious oxidative damage showed reduced IDO1 and TGFβ signaling signatures, along with decreased B cell- and T cell-associated TIGIT signatures after NACT. Conclusions: These findings identify oxidative DNA damage as a potential pretreatment biomarker associated with recurrence, survival, and tumor–immune state, supporting its potential to impact therapeutic decision-making in HGSOC.

  • A phase Ib/II single-arm study of cabozantinib plus dostarlimab in women with recurrent gynecologic carcinosarcoma

    by Kati A. Turner, Carson C. Edwards, Peter W. Ketch, Kaitlyn G. Dinkins, Anna Wilbanks, Charles A. Leath, Rebecca C. Arend, Michael D. Toboni